Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En fas 3 dubbelblind, placebokontrollerad studie (del A) med en öppen förlängning (del B) som utvärderar MM120 jämfört med placebo vid generaliserat ångestsyndrom

24 september 2026 uppdaterad av: Definium Therapeutics US, Inc.

En fas 3, multicenter, randomiserad, dubbelblind, placebokontrollerad, 12-veckorsstudie (del A) med en 40-veckors öppen förlängning (del B) som utvärderar effektiviteten och säkerheten för oral MM120 jämfört med placebo i Behandling av vuxna med generaliserat ångestsyndrom - Voyage

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Voyage

Studieöversikt

Status

Aktiv, inte rekryterande

Intervention / Behandling

Detaljerad beskrivning

The study will enroll up to 200 participants aged 18 to 74 years, inclusive with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) confirmed primary diagnosis of GAD and a minimum HAM-A total score of at least 20 at Screening and Baseline without clinically relevant medical or psychiatric history.

The study consists of a 12-week randomized, double-blind, single-dose administration period evaluating DT120 versus placebo, followed by a 40-week extension phase with the opportunity for open-label treatment. During this phase, participants will be monitored and evaluated for potential treatment with DT120 based on pre-specified safety and symptom severity criteria.

Studietyp

Interventionell

Inskrivning (Faktisk)

214

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Arizona
      • Gilbert, Arizona, Förenta staterna, 85234
        • Lighthouse Psychiatry
      • Scottsdale, Arizona, Förenta staterna, 85022
        • Scottsdale Research Institute
    • California
      • La Jolla, California, Förenta staterna, 92037
        • Kadima Neuropsychiatry Institute
      • San Francisco, California, Förenta staterna, 94158
        • UCSF Department of Neurology
      • Santa Monica, California, Förenta staterna, 90404
        • Psychedelic Science Institute
    • Colorado
      • Denver, Colorado, Förenta staterna, 80209
        • Mountain View
    • Florida
      • Jacksonville, Florida, Förenta staterna, 32256
        • Clinical Neuroscience Solutions Inc.
      • Lauderhill, Florida, Förenta staterna, 33319
        • Segal Trials
    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30331
        • Atlanta Center for Medical Research
      • Decatur, Georgia, Förenta staterna, 30030
        • iResearch Atlanta
      • Savannah, Georgia, Förenta staterna, 31405
        • CenExel iResearch, LLC
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60640
        • Uptown Research Institute
    • Massachusetts
      • Boston, Massachusetts, Förenta staterna, 02116
        • Adams Clinical Boston
      • Watertown, Massachusetts, Förenta staterna, 02472
        • Adams Clinical Watertown
    • New Jersey
      • Marlton, New Jersey, Förenta staterna, 08053
        • Hassman Research Institute
    • New York
      • New York, New York, Förenta staterna, 10021
        • Spectrum Neuroscience and Treatment Institute
      • New York, New York, Förenta staterna, 10032
        • New York State Psychiatric Institute (NYSPI)
      • New York, New York, Förenta staterna, 10029
        • Adams Clinical Harlem
      • The Bronx, New York, Förenta staterna, 10461
        • Adams Clinical Bronx
    • Ohio
      • Cleveland, Ohio, Förenta staterna, 44113
        • Cleveland Clinic Lutheran Hospital
    • Oregon
      • Portland, Oregon, Förenta staterna, 97210
        • Summit Headlands LLC
    • Pennsylvania
      • Moosic, Pennsylvania, Förenta staterna, 18507
        • Scranton Medical Institute
      • Philadelphia, Pennsylvania, Förenta staterna, 19104
        • Adams Clinical Philadelphia
    • South Carolina
      • North Charleston, South Carolina, Förenta staterna, 29405
        • Coastal Carolina Research Center
    • Tennessee
      • Memphis, Tennessee, Förenta staterna, 38119
        • Clinical Neuroscience Solutions, Inc.
    • Texas
      • Austin, Texas, Förenta staterna, 78712
        • University of Texas at Austin
      • Austin, Texas, Förenta staterna, 78759
        • BioBehavioral Research of Austin
      • Austin, Texas, Förenta staterna, 78737
        • Austin Clinical Trial Partners
      • Dallas, Texas, Förenta staterna, 75231
        • FutureSearch Trials of Dallas, LLC
      • DeSoto, Texas, Förenta staterna, 75115
        • Adams Clinical Dallas
    • Utah
      • Draper, Utah, Förenta staterna, 84020
        • Cedar Clinical Research
      • Orem, Utah, Förenta staterna, 84058
        • Inner Space Research
    • Vermont
      • Bennington, Vermont, Förenta staterna, 05201
        • Memory Clinic Inc.
    • Washington
      • Seattle, Washington, Förenta staterna, 98104
        • Seattle Neuropsychiatric Treatment Center

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 74 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Diagnosis of GAD per DSM-5
  2. Male or female aged 18 to 74
  3. HAM-A Total Score ≥20

Exclusion Criteria:

  1. Certain psychiatric disorders (other than generalized anxiety disorder)
  2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
  3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
  4. Any clinically significant unstable illness

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Trippel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Placebo-jämförare: Arm 1 - Placebo

A substance that is designed to have no therapeutic value

A substance that is designed to have no therapeutic value

Experimentell: Arm 2 - 100µg DT120

A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)

A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)

Andra namn:
  • lysergidtartrat
  • MM120
  • LSD D-Tartrate

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12
Tidsram: Baseline to Week 12

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

Baseline to Week 12

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Clinical Global Impression - Improvement (CGI-I) Scale score at each timepoint assessed during the 12-week double-blind period
Tidsram: Day 2 to Week 12

The CGI-I scale is used to measure the clinician's assessment of how much the participant's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises one item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening.

Day 2 to Week 12
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in Clinical Global Impression - Severity (CGI-S) Scale score
Tidsram: Baseline to Week 12

The CGI-S scale assesses the clinician's impression of the participant's current severity of illness relative to the clinician's experience with patients who have the same diagnosis. The CGI-S comprises one item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness.

Baseline to Week 12
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in Patient Global Impression - Severity (PGI-S) Scale score
Tidsram: Baseline to Week 12

The PGI scale is the patient-reported outcome (PRO) counterpart to the CGI scale. The PGI-S comprises one participant-completed item with 5 possible ratings (1-5) where a higher score indicates more severe illness.

Baseline to Week 12
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - EuroQol-5 Dimensions - 5 Levels (EQ-5D-5L)
Tidsram: Baseline to Week 12

The EuroQol 5 Dimension 5 Level (EQ-5D-5L) is a self-reported outcome measure used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS).

Baseline to Week 12
Change from Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) total score at each timepoint assessed during the double-blind period
Tidsram: Baseline to Week 12

The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning.

Baseline to Week 12
Percent of men and women with normal and abnormal sexual functioning at each timepoint assessed during the double-blind period
Tidsram: Baseline to Week 12

The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning.

Baseline to Week 12
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in MADRS total score
Tidsram: Baseline to Week 52

The MADRS is used to assess depression severity and to detect changes due to antidepressant treatment. The MADRS includes 10 clinician-completed items. Each of the 10 questions is scored with a range of 0-6 points. An item score of 0 indicates item not present or normal, while an item score of 6 indicates severe or continuous presence of the symptoms. The total possible score is 60, and higher scores represent a more severe condition.

Baseline to Week 52
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in Clinical Global Impression - Severity (CGI-S) Scale score
Tidsram: Baseline to Week 52

The CGI-S scale assesses the clinician's impression of the participant's current severity of illness relative to the clinician's experience with patients who have the same diagnosis. The CGI-S comprises one item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness.

Baseline to Week 52
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in Patient Global Impression - Severity (PGI-S) Scale score
Tidsram: Baseline to Week 52

The PGI scale is the patient-reported outcome (PRO) counterpart to the CGI scale. The PGI-S comprises one participant-completed item with 5 possible ratings (1-5) where a higher score indicates more severe illness.

Baseline to Week 52
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in WPAI-SHP
Tidsram: Baseline to Week 52

The WPAI-SHP is a 6-item questionnaire, with a recall period of the past 7 days. The WPAI measures impairments in both paid work and unpaid work. It measures absenteeism, presenteeism as well as impairment in unpaid activity because of the health problem under study.

Baseline to Week 52
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in EQ-5D-5L
Tidsram: Baseline to Week 52

The EuroQol 5 Dimension 5 Level (EQ-5D-5L) is a self-reported outcome measure used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS).

Baseline to Week 52
Percent men and women with normal and abnormal sexual functioning at each timepoint assessed during the open-label period
Tidsram: 40 week open label period

The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning.

40 week open label period
Change from Baseline in HAM-A total score at Week 8, Week 4, Week 2, and Week 1
Tidsram: Week 8, Week 4, Week 2, and Week 1

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

Week 8, Week 4, Week 2, and Week 1
HAM-A response (reduction from Baseline score of ≥50%) at each timepoint assessed during the 12-week double-blind period
Tidsram: Baseline to Week 12

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

Baseline to Week 12
HAM-A remission (total score ≤7) at each timepoint assessed during the 12-week double-blind treatment period
Tidsram: Baseline to Week 12

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

Baseline to Week 12
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - Montgomery-Åsberg Depression Rating Scale (MADRS) total score
Tidsram: Baseline to Week 12

The MADRS is used to assess depression severity and to detect changes due to antidepressant treatment. The MADRS includes 10 clinician-completed items. Each of the 10 questions is scored with a range of 0-6 points. An item score of 0 indicates item not present or normal, while an item score of 6 indicates severe or continuous presence of the symptoms. The total possible score is 60, and higher scores represent a more severe condition.

Baseline to Week 12
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in -Work Productivity and Activity Impairment Specific Health Problem Questionnaire (WPAI-SHP)
Tidsram: Baseline to Week 12

The WPAI-SHP is a 6-item questionnaire, with a recall period of the past 7 days. The WPAI measures impairments in both paid work and unpaid work. It measures absenteeism, presenteeism as well as impairment in unpaid activity because of the health problem under study.

Baseline to Week 12
Percent of participants requiring one, two, three, four, or five doses of DT120 during the 52-week study (Part A and Part B) as assessed by participants meeting protocol-specified retreatment criteria during the 40-week open-label period
Tidsram: Day 1 to Week 52

Percent of participants requiring one, two, three, four, or five doses of DT120 during the 52-week study (Part A and Part B) as assessed by participants meeting protocol-specified retreatment criteria during the 40-week open-label period

Day 1 to Week 52
Time to first treatment or lack of efficacy in the open-label period (Part B)
Tidsram: Day 1 to Week 52

Measured as time from first dosing in the Double-blind period to participant meeting HAM-A criteria for re-dose or meeting criteria for lack of efficacy

Day 1 to Week 52
Need for DT120 treatment as assessed by the average number of DT120 treatments during the study
Tidsram: Day 1 to Week 52

Average number of treatments assessed from first dose in the double-blind period through completion of the open label extension.

Day 1 to Week 52
HAM-A response (reduction from Baseline score of ≥50%) at each timepoint assessed during the 40-week open-label period
Tidsram: 40 week open label period

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

40 week open label period
HAM-A remission (total score ≤7) at each timepoint assessed during the 40-week open-label period
Tidsram: 40 week open label period

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

40 week open label period
CSFQ-14 total score at each timepoint assessed during the open-label period
Tidsram: 40 week open label period

The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning.

40 week open label period

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

11 december 2024

Primärt slutförande (Faktisk)

15 juli 2026

Avslutad studie (Beräknad)

1 april 2027

Studieregistreringsdatum

Först inskickad

16 december 2024

Först inskickad som uppfyllde QC-kriterierna

16 december 2024

Första postat (Faktisk)

18 december 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

25 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

24 september 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • MM120-300

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera